Resverlogix Corp
13
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
70.0%
-16.5% vs industry average
8%
1 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of Apabetalone in Subjects With Long -COVID
Role: lead
An Open-Label Study of Apabetalone in Covid Infection
Role: lead
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Role: lead
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
Role: lead
Apabetalone for Pulmonary Arterial Hypertension
Role: collaborator
Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Role: lead
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Role: lead
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
Role: collaborator
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Role: lead
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Role: lead
The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Role: lead
ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Role: lead
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Role: lead
All 13 trials loaded